Abstract
The management of Crohn’s disease (CD) using anti-tumour necrosis factor therapy in tuberculosis (TB)-endemic regions poses major clinical challenges due to the risk of latent TB infection reactivation. This bibliometric–systematic literature review synthesised evidence from 17 peer-reviewed studies (2020–2025) evaluating adalimumab administered with concurrent prophylactic antitubercular therapy. Thematic synthesis and bibliometric mapping using VOSviewer demonstrated that adalimumab achieved 60–85% clinical remission in moderate-to-severe CD and axial spondyloarthritis while enhancing mucosal healing. However, 1–3% of patients developed active TB despite appropriate screening and isoniazid prophylaxis, revealing false-negative diagnostics and partial chemoprophylaxis protection. These findings highlight the need for region-specific frameworks integrating multimodal screening, targeted prophylaxis and ongoing clinical surveillance. Adalimumab remains a cornerstone biologic in TB-endemic settings, but its safe use requires adaptive, context-driven protocols emphasising vigilant risk mitigation.
Publication details
- DOI
- 10.18295/2075-0528.2971
- Journal
- Sultan Qaboos University Medical Journal, 26(1), 171-183
- Publisher
- Sultan Qaboos University
- Open access
- Gold open access
- License
- CC BY-ND 4.0
Cite this article
APA 7
Shofa, N. M., Mudjari, N. S., Ekawati, R., Arianti, A., Mufida, A. Z., Widodo, B., & Sugihartono, T. (2026). Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review. Sultan Qaboos University Medical Journal, 26(1), 171-183. https://doi.org/10.18295/2075-0528.2971
MLA 9
Shofa, Nyimas Maida, et al. "Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review." Sultan Qaboos University Medical Journal, vol. 26, no. 1, 2026, pp. 171-183. https://doi.org/10.18295/2075-0528.2971.
Chicago (author–date)
Shofa, Nyimas Maida, Nurike Setiyari Mudjari, Rusdiyana Ekawati, Arianti Arianti, Annisa Zahra Mufida, Budi Widodo, and Titong Sugihartono. 2026. "Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review." Sultan Qaboos University Medical Journal 26 (1): 171-183. https://doi.org/10.18295/2075-0528.2971.
Harvard
Shofa, N. M., Mudjari, N. S., Ekawati, R., Arianti, A., Mufida, A. Z., Widodo, B. and Sugihartono, T. (2026) 'Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review', Sultan Qaboos University Medical Journal, 26(1), pp. 171-183. doi:10.18295/2075-0528.2971.
Vancouver
Shofa NM, Mudjari NS, Ekawati R, Arianti A, Mufida AZ, Widodo B, et al. Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review. Sultan Qaboos University Medical Journal. 2026;26(1):171-183. doi:10.18295/2075-0528.2971
IEEE
N. M. Shofa, N. S. Mudjari, R. Ekawati, A. Arianti, A. Z. Mufida, B. Widodo, and T. Sugihartono, "Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review," Sultan Qaboos University Medical Journal, vol. 26, no. 1, pp. 171-183, 2026, doi: 10.18295/2075-0528.2971.